echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Roche's "open-ended cancer" therapy has been approved by the European Union.

    Roche's "open-ended cancer" therapy has been approved by the European Union.

    • Last Update: 2020-08-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    August 4, 2020 / Pharmaceutical Information List: Teg Pharmaceutical H shares issue price: HK$100/share raised HK$10.7 billion; Daily fresh medicine news, quick reading with you to pay attention to! Policy Briefing State Document Issued affecting the performance of primary care doctors 3 days, the National Health And Health Commission issued "on the further strengthening of smoke-free medical and health institutions construction notice", the deployment of new tasks, requiring all medical and health institutions and medical personnel to play a model leading role, public health content, performance pay or will be affected.
    (National Health And Health Commission) has observed the issue price of Tiger Pharma H shares: HK$100/share raising HK$10.7 billion Tag Pharmaceuticals announced on the 3rd that it has been confirmed that it will be listed on the main board of the Hong Kong Stock Exchange on August 7, 2020, with the final price of foreign shares (H shares) listed abroad at HK$100.00/share.
    the IPO is expected to issue 107 million new shares, or 12.5 per cent of the total number of shares after the offering, and to raise HK$10.7 billion, with Merrill Lynch Far East, Haitong International, CITIC Lyons and CITIC Hong Kong as co-sponsors.
    (Tiger Pharmaceuticals Announcement) faced a number of lawsuits Furen Pharmaceuticals overdue debt of 3.8 billion Furen Pharmaceuticals issued a notice that recently through the China Securities Registration and Settlement Co., Ltd. Shanghai Branch System inquiry, learned that the controlling shareholder Furen Group was judicially auctioned 14.4 million shares have completed the transfer registration procedures.
    , the overdue debt of Furen Group is estimated at about $3,845 million, according to the company's announcement.
    due to overdue debts, Furen Group is facing a number of lawsuits involving an amount of about 3.8 billion yuan, the specific amount of which needs to be further verified.
    (Auxiliary Pharmaceuticals Announcement) First Sound Pharmaceuticals for $170 million to obtain an exclusive license for the new tumor drug CDK4/6 inhibitor trilaciclib 3 days, G1 and Syngenta Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of all adaptations in the Greater China region of Trilaciclib.
    terms of the agreement, G1 will receive an advance payment of $14 million and be eligible for development and commercial milestone payments of up to $156 million.
    Trilaciclib is a kinase 4/6 (CDK4/6) inhibitor that relies on cell cycle proteins and is designed to be added to standard treatments to reduce adverse bone marrow inhibition reactions.
    Gene Therapy Innovation completed more than $20 million B round of financing Junlian Capital lead investment 3 days, industry news, gene therapy new Exegenesis Bio recently completed more than $20 million round B financing.
    This round of financing is led by Junlian Capital, Taifu Capital, Kaitai Capital, Boyuan Capital and Fengqiyun, and Hao Yue Capital serves as the exclusive financial advisor for this round of financing.
    it is understood that the current round of financing will be used to promote the company's many gene therapy pipeline clinical and research and development.
    (Pharmaceutical Mission) Pharmaceutical News Lilly launched a phase III clinical trial of new coronary virus and antibodies recently, Lilly has launched phase III BLAZE-2 trial in the United States, which will be conducted with the help of the U.S. government, mainly in people at high risk of infection and poor health - long-term care institutions (usually nursing homes and assisted living communities) residents and staff, testing and antibody LY-CoV555 can prevent new corona virus infection and treatment COVID-19.
    (Sina Pharmaceutical News) CymaBay's phase III trial of PPAR sedatives reached its main end point, CymaBay announced that it had reached the end of phase III of its trial of the new drug seladelpar.
    this was a double-blind, placebo-controlled randomized study that assessed the safety and effectiveness of seladelpar in the treatment of primary biliary tartitis.
    Seladelpar is an oral, powerful, selective peroxidase proliferation-activated recepor (PPAR) agitant.
    (Sina Pharmaceutical News) Rozlytrek "open-ended cancer" therapy Rozlytrek was approved by the European Union 3, Roche announced that the European Commission has granted Rozlytrek conditional listing license for adults 12 years and older with neurotrophic tyrosine receptaclease gene fusion of solid tumors and pediatric patients, these patients have local late stage, metastatic solid tumor or surgical removal may lead to serious complications, and have not received NTRK inhibitor treatment, no satisfactory treatment options.
    (Xinhua) -- Jansen Innovation Therapy has been approved to treat patients with suicidal depression, Johnson and Johnson announced today that the FDA has approved a new drug application for spravato CIII nasal spray, in combination with oral antidepressants, to treat depressive symptoms in adults with acute suicidal ideas or behavior.
    (Drug Mingkangde) Mercado/ Weisser submitted Lenvima's new adaptive application in Japan and Mercado's Japanese subsidiary MSD K.K. recently jointly announced that it has submitted a new adaptive application for the cancer drug Lenvima in Japan, a multi-receptopic tyrosine kinase inhibitor used to treat irresectable thymus cancer.
    (Biological Valley) Colum Pharmaceuticals LAG-3 monoantigen approved clinical 3, CDE official website shows that Colum Pharmaceuticals subsidiary Columbotai / Anyuan Pharmaceuticals declared LAG-3 antibody KL-A289 injections have been clinically implied license for use in advanced solid tumors.
    (CDE) Shanghai Pharma Formishatan tablets through generic drug consistency evaluation Shanghai Pharma issued a notice on the 3rd, said that its wholly-owned subsidiary Xinyi balance for mishatan tablets by the drug supplement application approval, the first drug through generic consistency evaluation.
    is mainly used in the treatment of primary hypertension.
    (Shanghai Pharmaceutical Announcement) nine-code pharmaceutical sodium sodium intestinal tablets recently, nine-code pharmaceutical announced that the company recently received the State Drug Administration approved the issuance of the "drug supplement application approval notice", the company's products "torrazozo sodium intestinal tablets" through the quality of generic drugs and efficacy consistency evaluation.
    (Nine Pharma Announcement) Zeyu Pharmaceuticals to carry out Donafini and KN046 joint treatment of advanced digestive tract solid tumor clinical trial 4, Zeyu Pharmaceuticals issued a notice that the company recently received the State Drug Administration approved the issuance of the "Drug Clinical Trial Approval Notice."
    was approved to conduct a clinical trial of toluene sulfonate donapine tablets in a joint treatment of advanced digestive tract solid tumors with KN046 injections.
    (Zeyin Pharmaceutical Announcement) Xinda Bio 3 anti-tumor new drug clinical application was accepted 4 days, CDE website publicity shows that Xinda Bio submitted three new anti-tumor drug clinical trial application and received acceptance, including PD-1 inhibitor Sidili monoanti injection, CTLA-4 antibody IBI310, and anti-tumor biological new drug IBI102.
    , IBI102 is the first time a clinical report has been declared in China.
    (Pharmaceutical Mission) Qilu lulu acid sidina non-tablets were approved in recent days, Qilu Pharmaceuticals according to the imitation of 4 categories of reported production of sourdina non-tablet processing status changed to "in the approval", is expected to be approved in recent days and treated as the same.
    acid sic acid sidina non-tablets for the third batch of collection varieties, Minet data show that in 2019 China's urban retail pharmacy terminal Xidina non-sales of more than 2.3 billion yuan, an increase of 7.42 percent year-on-year.
    (Minet) China biopharmaceutical Adelfowe ester capsule through consistency evaluation On August 4, China Biopharmaceuticals announced that the Group's hepatitis B drug "Adelfove ester capsule" (trademark name: zheng) has been issued by the State Drug Administration drug supplement application approval notice, becoming the first product of the same variety through the evaluation of the quality and efficacy of generic drugs consistency.
    (China Biopharmaceutical Announcement) Hengrui Pharmaceutical two drugs approved by the clinical trial notice 3, Hengrui Pharmaceuticals announced that the company's meth sulfonate apatini tablets and fluoroparin capsules received the Approval Notice of Drug Clinical Trials issued by the State Drug Administration, and will conduct clinical trials in the near future.
    (Hengrui Pharmaceutical Bulletin)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.